Enzon Pharmaceuticals (OTCMKTS:ENZN) Shares Pass Above 200 Day Moving Average – Here’s What Happened

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.10 and traded as high as $6.25. Enzon Pharmaceuticals shares last traded at $6.1916, with a volume of 1,584 shares traded.

Enzon Pharmaceuticals Stock Performance

The firm has a market capitalization of $459.51 million, a P/E ratio of -88.44 and a beta of 0.20. The stock has a 50-day moving average of $0.19 and a 200 day moving average of $0.10.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.02) EPS for the quarter.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.